By CB2 Insights Inc. on Wednesday, 10 July 2019
Category: Technology Platforms

CB2 Insights ready to move to Phase two of study with primary care physicians tool

viewCB2 Insights Inc.

(CSE: CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver to discuss the company moving into phase 2 of the integration of their program into the Juno platform.

Sekar tells Proactive about the results of phase 1 and what they were hearing from Physicians using the system. 

CSE:CBII

Market: CSE
Market Cap: $9.6 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 12/17/2019

2 min read

Related Posts